Takeda Pharmaceutical Co., Ltd. (TAK)
18.10
+0.29
(+1.63%)
USD |
NYSE |
Oct 06, 16:00
18.10
0.00 (0.00%)
Pre-Market: 20:00
Takeda Pharmaceutical Gross Profit Margin (Quarterly) : 57.57% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 57.57% |
| March 31, 2026 | 59.01% |
| December 31, 2025 | 54.43% |
| September 30, 2025 | 47.41% |
| June 30, 2025 | 53.35% |
| March 31, 2025 | 51.49% |
| December 31, 2024 | 51.77% |
| September 30, 2024 | 54.36% |
| June 30, 2024 | 54.49% |
| March 31, 2024 | 50.87% |
| December 31, 2023 | 53.81% |
| September 30, 2023 | 44.03% |
| June 30, 2023 | 57.44% |
| March 31, 2023 | 53.67% |
| December 31, 2022 | 57.00% |
| September 30, 2022 | 55.32% |
| June 30, 2022 | 56.38% |
| March 31, 2022 | 47.59% |
| December 31, 2021 | 55.68% |
| September 30, 2021 | 55.20% |
| June 30, 2021 | 63.77% |
| March 31, 2021 | 52.26% |
| December 31, 2020 | 57.86% |
| September 30, 2020 | 55.19% |
| June 30, 2020 | 57.31% |
| Date | Value |
|---|---|
| March 31, 2020 | 58.57% |
| December 31, 2019 | 55.37% |
| September 30, 2019 | 53.93% |
| June 30, 2019 | 51.30% |
| March 31, 2019 | 46.86% |
| December 31, 2018 | 66.04% |
| September 30, 2018 | 68.66% |
| June 30, 2018 | 67.85% |
| March 31, 2018 | 66.17% |
| December 31, 2017 | 63.65% |
| September 30, 2017 | 66.23% |
| June 30, 2017 | 65.79% |
| March 31, 2017 | 60.38% |
| December 31, 2016 | 62.49% |
| September 30, 2016 | 54.74% |
| June 30, 2016 | 62.23% |
| March 31, 2016 | 60.15% |
| December 31, 2015 | 64.20% |
| September 30, 2015 | 63.76% |
| June 30, 2015 | 65.38% |
| March 31, 2015 | 57.86% |
| December 31, 2014 | 58.52% |
| September 30, 2014 | 63.33% |
| June 30, 2014 | 63.81% |
| March 31, 2014 | 67.99% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Sanofi | -- |
| Daiichi Sankyo Co., Ltd. | 78.37% |
| Ono Pharmaceutical Co., Ltd. | 75.31% |
| Astellas Pharma, Inc. | 75.29% |
| Eisai Co., Ltd. | 78.20% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -2.19% |
| Return on Assets | -1.07% |
| Return on Invested Capital | -1.32% |
| Profit Margin (Quarterly) | 9.28% |
| Operating Margin (Quarterly) | 20.36% |
| Return on Net Operating Assets | -1.21% |